Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
FDA APPROVES HIGH-DOSE WEGOVY March 2026 The new 7.2 mg dose is triple the previous highest dose of 2.4 mg The issue: Average weight loss with the highest dose of Wegovy is 13% to 16%, while its main competitor, Zepbound, has a mean weight loss of 20% to 22% at its highest dose Why this matters: A study comparing Wegovy doses of 2.4 mg and 7.2 mg found that the higher dose caused more weight loss, but also more gastrointestinal side effects and dysaesthesia
Long-acting, subcutaneously administered, PYY RA are undergoing early phase clinical trials as obesity treatments either alone or in combination with GLP-1 RA (Table 1, NCT02568306 and NCT03574584)
The Super Myers Cocktail starts there and goes further, adding glutathione for cellular detox and trace minerals zinc, copper, manganese, and selenium your body needs in smaller but critical amounts
Talking to Your GP or Specialist About Weight Management Options Speak to your GP about licensed options such as semaglutide 2.4 mg (Wegovy) under NICE TA875 or tirzepatide (Mounjaro)
If recommended, they should be properly fitted by a healthcare professional, and are contraindicated in certain conditions including peripheral arterial disease and severe neuropathy
However, the evidence regarding this long-standing treatment option is limited and is more based on clinical practice than on high-quality RCTs
